This press section is intended for journalists and investors for a professional use.

WHAT’S NEW
AT VOLUNTIS ?

ABOUT VOLUNTIS

Voluntis is dedicated to developing companion software that empowers patients to self-manage their chronic disease in collaboration with their medical team.

DOWNLOAD PRESS KIT

Working on a Voluntis story? We can help.

  • Meet Oleena®

    Meet Insulia®

  • What is companion software?

    Tomorrowland: medical treatment in 2020

Meet Oleena®

Meet Insulia®

What is companion software?

Tomorrowland: medical treatment in 2020

PRESS RELEASES

March 2021

2020 annual results in line with the roadmap, demonstrating the success of the new strategy, and confirmed confidence in the plan

March 2021

Broward Health and Voluntis launch a new clinical evaluation program on digital therapeutics for metastatic breast cancer

March 2021

Voluntis announces the organization of meetings with institutional investors accompanied by brokerage firm Gilbert Dupont

March 2021

Voluntis strengthens its global customer support services in collaboration with Zendesk

March 2021

Publication of a new study on Voluntis by brokerage firm Bryan, Garnier & Co

March 2021

Initiation of Voluntis stock coverage by the brokerage firm Gilbert Dupont

February 2021

First day of trading of Voluntis shares on the Euronext Growth Paris market

February 2021

Transfer of Voluntis shares to the Euronext Growth Paris market effective on February 17, 2021

February 2021

Voluntis announces issuance of European patent for drug dosing support with its Theraxium digital therapeutic platform

January 2021

Commercial successes and financial operations put Voluntis on track to deliver on its strategic roadmap in 2021 and beyond

December 2020

Voluntis obtains €3 million of additional non-dilutive loans and optimizes its existing financing

December 2020

Voluntis shareholders’ approval of the securities listing transfer project to the Euronext Growth market in Paris

December 2020

Transfert du contrat de liquidité

November 2020

Informations relatives au nombre total de droits de vote et d’actions

November 2020

Voluntis successfully completes a capital increase of €5.9 million and finalizes the financing of its strategic roadmap

November 2020

Launch of a new R&D Program to extend the Theraxium platform supported by a loan from Bpifrance

November 2020

Voluntis receives CE Mark for Oleena, key milestone to the future commercialization of its digital therapeutics for oncology

November 2020

Voluntis extends its digital therapeutics cloud infrastructure worldwide with Microsoft

October 2020

Voluntis and Redox enter into new partnership to enable interoperability of digital therapeutics with Electronic Health Records

October 2020

Project to transfer the listing of securities to the Euronext Growth market in Paris

October 2020

Voluntis announces issuance of US patent for the proprietary algorithm engine of its Theraxium digital therapeutic platform

September 2020

Voluntis announces record commercial bookings and a tripling of its sales invoicing in 2020

September 2020

Promising first-half results for 2020 and record commercial invoicing

September 2020

Voluntis obtains € 2 million in non-dilutive financing

September 2020

Appointment of Guillaume Floch as Chief Financial Officer of Voluntis

July 2020

Voluntis announces changes to its governance

July 2020

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

July 2020

Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate Finance

July 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

June 2020

Application de droits de vote double et impact sur la répartition des droits de vote

June 2020

Erratum – Rapport financier annuel 2019

June 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

May 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

April 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

March 2020

Voluntis reports its 2019 financial results

March 2020

Voluntis announces its new strategic roadmap

March 2020

Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology

February 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

January 2020

Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate Finance

January 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

December 2019

Voluntis Announces New Pharma Collaboration in Oncology

December 2019

Voluntis Collaborates with Salesforce to Introduce Full-Service Platform for Digital Therapeutics Prescription and Reimbursement

December 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

November 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

October 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Voluntis reports Business Review and Financial Results for first half of 2019

September 2019

Voluntis - Notice of Business review and results for the first half of 2019 Results to be announced on Thursday 19 September 2019 at 8:00am CEST

September 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

August 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

July 2019

Voluntis Announces Market Authorization for Oleena™, First Digital Therapeutic in Oncology

July 2019

Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate Finance

July 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

July 2019

Voluntis maintains a strong and promising view for the company’s future

June 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

May 2019

Voluntis : Mise à disposition des documents préparatoires à l’Assemblée Générale mixte du 24 mai 2019

May 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

April 2019

Voluntis : Mise à disposition du Document de Référence 2018

April 2019

Voluntis appoints Berkley Nelson as Chief Growth Officer

March 2019

Voluntis – Annual results 2018

March 2019

Voluntis announces end of Roche Pharma France collaboration for ZEMY solution

March 2019

Voluntis receives CE Mark to add NPH/isophane insulin to Insulia

March 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

February 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

January 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

December 2018

AbbVie and Voluntis to develop companion digital therapeutics

December 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

November 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

October 2018

Voluntis and AstraZeneca win prestigious Prix Galien MedStartUp Award for ‘Best Patient Engagement Technologies’ for eCO

October 2018

Jan Berger, MD, and Roberta Herman, MD, join Voluntis’ Board of Directors

October 2018

Voluntis announces end of multi-cancer extension for solution developed with Roche Pharma France

October 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

September 2018

First-half 2018: expanded and strengthened abilities to pursue future growth

August 2018

Voluntis extends partnership with AstraZeneca in digital therapeutics for oncology

August 2018

Voluntis releases upgraded version of Insulia to improve user experience, including Spanish

August 2018

Information relative au nombre total de droits de vote et d’actions composant le capital social

July 2018

Voluntis announces the launch of Theraxium Oncology, an innovative digital platform for symptom management

July 2018

Results of the eCO trial published in the Journal of Clinical Oncology Informatics

July 2018

Information relative au nombre total de droits de vote et d’actions composant le capital social

May 2018

Voluntis successfully completes its IPO and raises €30.1m on the regulated market of Euronext in Paris

May 2018

Voluntis signs contract with US payer WellDyneRx for coverage of a digital therapeutic

April 2018

Voluntis announces the registration of its document de base, launching its initial public offering process on Euronext’s regulated market in Paris

March 2018

Voluntis and Roche Pharma France reinvent cancer patient support with digital therapeutics

January 2018

Voluntis and WellDoc Announce Partnership to Combine Diabetes Digital Therapeutic Offerings

December 2017

Voluntis launches Insulia Savings Program, making Insulia available at $0 copay

November 2017

Voluntis to integrate Insulia® with Onduo virtual diabetes clinic

November 2017

Insulia receives FDA clearance and CE mark to integrate Basaglar and Tresiba

October 2017

Digital Therapeutics Alliance Established to Advance Novel Technologies Aimed at Transforming Patient Clinical Outcomes

July 2017

Insulia® receives FDA clearance and CE mark to integrate Toujeo®

June 2017

Voluntis and Ascensia Diabetes Care announce technology partnership to help optimize insulin management for people with Type 2 diabetes

April 2017

Voluntis adds Scott Honken to Leadership Team to strengthen payer & provider focus

March 2017

Voluntis and Sanofi announce a global alliance to deliver digital insulin titration solutions for people with type 2 diabetes

February 2017

Voluntis and Livongo Partner to Deliver Insulin Titration App

VOLUNTIS IN THE NEWS

February 2021 - Tic Pharma

Partenariats industriels et focus sur l'oncologie: la recette de Voluntis pour atteindre l'équilibre en 2021

January 2021 - Digital Health Today

Digital Therapeutics Edition: Prescription Digital Therapeutics with Pierre Leurent, CEO of Voluntis

March 2020 - Medgazette 24

Digital Therapeutics Get a Boost in Oncology

January 2020 - MedCity News

Digital health, digital therapeutics, digital medicines - what's in a name?

March 2019 - Tic Pharma

Diabète : Sanofi obtient de premiers résultats "prometteurs" avec ses outils connectés

October 2019 - Forbes

Digital Medecine Movement Is Growing Up And That's A Good Thing

August 2019 - Mobi Health News

Voluntis' symptom management platform for cancer patients receives FDA's blessing

August 2019 - Forbes

Digital therapeutics hot summer with major IPOs and first oncology app

December 2018 - Insulin Nation

Basal Insulin Management is not easy. These new tools could help

March 2018 - FierceBiotech

Roche, Voluntis expand digital therapeutics pact into solid tumors

January 2018 - Pharmacy Practice News

Adherence Goes Hi-Tech

February 2018 - McKinsey & Company

Digital Therapeutics: Preparing for Takeoff

February 2018 - The Economist

A Revolution in Health Care is Coming

November 2017 - Pharmacy Times

Insulin Dosing Apps Are on Their Way

November 2017 - Mobihealthnews

Voluntis gets FDA clearance to add last two basal insulins to app

November 2017 - Pharmaphorum

7 questions: the Digital Therapeutic Alliance’s Pierre Leurent

November 2017 - Cancer Therapy Advisor

Mobile Apps: The Future of Cancer Care?

June 2017 - Endocrine Today

Ascensia, Voluntis to Combine Technologies

March 2017 - Close Concerns

Sanofi and Voluntis Announce Expanded Partnership

January 2017 - A Sweet Life

Insulia, Software by Prescription for Type 2 Diabetes Management

BRAND ASSETS